Sitagliptin and vildagliptin: Efficacy of therapy in type 2 diabetes

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 2, Issue 3, 2008, Pages 162-171

  Kirk, Julienne K ^a   Oldham, Elizabeth C ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

A1C; Diabetes; Dipeptidyl peptidase 4 (DPP 4) inhibitor; Efficacy; Sitagliptin; Vildagliptin

Indexed keywords

ACARBOSE; ALOGLIPTIN; ANTIDIABETIC AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EFFICIB; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; PHOSPHODIESTERASE IV INHIBITOR; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VELMETIA; VILDAGLIPTIN; XELEVIA;

ADD ON THERAPY; ARTHRALGIA; CLINICAL TRIAL; COUGHING; DIET THERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LOW DRUG DOSE; MEDLINE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT GAIN;

EID: 58149119500     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221408786241784     Document Type: Review

References (55)

1. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
2. Nathan DM, Buse JB, Davidson MB, Heine RJ, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29: 1963-1072.
3. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940.
4. Nauchk M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin- dependent) diabetes. Diabetologia 1986; 29: 46-52.
5. Ahren B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract 2008; 62: S8-14.
6. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003; 12: 87-100.
7. Campbell RK. Rationale for dipetidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmcother 2007; 41: 51-60.
8. European Medical Agency. European Public Assessment Report authorized medicinal products for human use. Available from http://www.emea.europa.eu/humandocs/Humans/EPAR/januvia/januvia.htm accessed 14 May, 2008.
9. European Medical Agency. European Public Assessment Report authorized medicinal products for human use. Available from http://www.emea.europa.eu/humandocs/Humans/EPAR/galvus/galvus.htm accessed 14 May, 2008.
10. European Medical Agency. Committee for Medicinal Products for Human Use Post-Authorization Summary of Positive Opinion for Januvia. Available from http://www.emea.europa.eu/pdfs/human/opinion/ Januvia_53120907en.pdf accessed 14 May, 2008.
11. European Medical Agency. http://www.emea.europa.eu/ accessed 14 May, 2008.
12. Chyan YJ, Shuang LM. Dipeptidyl peptidase-IV inhibitors: An evolving treatment for type 2 diabetes from the incretin concept. Recent Patents Endocr Metabol Immun Drug Discov 2007; 1: 15-24.
13. Klein, T., Blasér, A., Rudolph, B., Jens, S., Kromer, W.: WO08028914 (2008).
14. Amatruda, J., Fong, T., Moller, D., Thornberry, N.: EP0752064 (2006).
15. John, A.M., Fong, T.M., Moller, D.E., Thornberry, N.A.: EP1879582 (2008).
16. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835.
17. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotopic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at nearphysiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917.
18. Nauck M, Schmidt WE, Ebert R. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab 1989; 69: 654-662.
19. Triplitt C, Wright A, Chiquette E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors; Potential new therapies for type 2 diabetes mellitus. Pharmacotherapy 2006; 26: 360-374.
20. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61: 171-180.
21. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571.
22. Aschner P, Kipnes M, Lunceford J, Sanchez M, Mickel C, Williams-Herman D. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
23. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diab Res Clin Prac 2008; 79: 291-298.
24. Rosenstock J, Brazg R, Andryuk P, Kaifeng L, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24 week, multicenter, randomized, double blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 1556-1568.
25. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-2643.
26. Goldstein B, Feinglos M, Lunceford J, Johnson J, Williams-Herman D. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987.
27. Nauck M, Meininger G, Sheng D, Terranella L, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin, compared with sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
28. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diab Obes Metab 2007; 9: 733-745.
29. Scott R, Loeys T, Davies M, Engel S. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diab Obes Metabol 2008 Jan 14 (Epub ahead of print).
30. Raz I, Chen Y, Wu M, et al. Efficacy and safety of the sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008; 24: 537-550.
31. Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-875.
32. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with depeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692-698.
33. Ahren B, Landin-Olsson M, Jansson P, Svensson M, Holmes D, Schweizer J. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
34. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; 39: 218-223.
35. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diab Res Clin Prac 2007; 76: 132-138.
36. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naïve elderly patients. Diabetes Care 2007; 30: 3017-3022.
37. Scherbaum WA, Schweizer, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycemia. Diabetes Obes Metab 2008 Feb 1 (Epub ahead of print).
38. Scherbaum WA, Schweizer, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during a 2-year treatment of patients with type 2 diabetes and mild hyperglycemia. Diabetes Obes Metab 2008 Mar 18 (Epub ahead of print).
39. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
40. Ahren B, Gomis R, Standl E, Mills D, Schwiezer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF 237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880.
41. Bolli G, Dotta F, Rochotte E. Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008; 10: 82-90.
42. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.
43. Fonseca V. Schweizer A. Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetolgia 2007; 50: 1148-1155.
44. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-441.
45. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007; 24: 955-961.
46. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildaglipitin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care 2007; 30: 217-223.
47. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 166-174.
48. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008 Feb 18 (Epub ahead of print).
49. Deacon CF, Ahren B, Holst JJ. Inhibition of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004; 13: 1091-1102.
50. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Diabetes 2005; 54: 2988-2994.
51. Januvia Package insert. Whitehouse Station, New Jersey, Copyright 2007.
52. Miller, St Onge, Taylor, DPP-IV inhibitors: A review of sitagliptin, vildagliptin, alogliptin, and saxagliptin. Modern Medicine 2008; 43: http://www.modernmedicine.com/ accessed 14 May, 2008.
53. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; CD006739: 1-131.
54. Panina G. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond. Diabetes Obes Metab 2008; 9: 32-39.
55. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30-35.